NextBigFuture

Trying to Stabilize Populations Before It is Too Late

Taiwan, South Korea and China have critically low fertility rates below 1.0. Japan is also very low (1.15) and has had low ...
PharmiWeb

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer

BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...

China is rising, but the challenge is not from China alone

Rival centres of power are emerging, which broadly share China’s desire to undermine American hegemony, to cut the US down to ...

ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cance…

ENHERTU Followed by THP Before Surgery Resulted in Pathologic Complete Response in 67% of Patients w/High-Risk HER2 Positive ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early ...

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before ...

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 ...

Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in ...

Wellness Wins: I Often Get Asked What My Ride-or-Die Supplement Is – and My Answer Is MyOva, Every Time

Each MyOva Myoplus serving contains 4000mg of Myo-inositol, which Reif describes as "a well-researched supplement for PCOS" ...